Switch theme
Sign up to access all valuation multiples
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. Through its subsidiaries, the company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.
1970
15.7K+
LTM Revenue $2.5B
LTM EBITDA $516M
$8.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Chemed has a last 12-month revenue (LTM) of $2.5B and a last 12-month EBITDA of $516M.
In the most recent fiscal year, Chemed achieved revenue of $2.4B and an EBITDA of $464M.
Chemed expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Chemed valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.5B | XXX | $2.4B | XXX | XXX | XXX |
| Gross Profit | $877M | XXX | $854M | XXX | XXX | XXX |
| Gross Margin | 35% | XXX | 35% | XXX | XXX | XXX |
| EBITDA | $516M | XXX | $464M | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 19% | XXX | XXX | XXX |
| EBIT | $451M | XXX | $367M | XXX | XXX | XXX |
| EBIT Margin | 18% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $318M | XXX | $302M | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Chemed's stock price is $575.
Chemed has current market cap of $8.4B, and EV of $8.4B.
See Chemed trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8.4B | $8.4B | XXX | XXX | XXX | XXX | $24.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Chemed has market cap of $8.4B and EV of $8.4B.
Chemed's trades at 3.4x EV/Revenue multiple, and 18.1x EV/EBITDA.
Equity research analysts estimate Chemed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Chemed has a P/E ratio of 26.4x.
See valuation multiples for Chemed and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8.4B | XXX | $8.4B | XXX | XXX | XXX |
| EV (current) | $8.4B | XXX | $8.4B | XXX | XXX | XXX |
| EV/Revenue | 3.3x | XXX | 3.4x | XXX | XXX | XXX |
| EV/EBITDA | 16.3x | XXX | 18.1x | XXX | XXX | XXX |
| EV/EBIT | 18.6x | XXX | 22.8x | XXX | XXX | XXX |
| EV/Gross Profit | 9.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 26.4x | XXX | 27.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 22.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialChemed's last 12 month revenue growth is 7%
Chemed's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $31K for the same period.
Chemed's rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Chemed's rule of X is 39% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Chemed and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | 13% | XXX | XXX | XXX |
| Rule of 40 | 26% | XXX | 27% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 39% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $31K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 20% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| National Healthcare Corp | XXX | XXX | XXX | XXX | XXX | XXX |
| Regis Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Maternus-Kliniken | XXX | XXX | XXX | XXX | XXX | XXX |
| Addus HomeCare | XXX | XXX | XXX | XXX | XXX | XXX |
| Amedisys | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Chemed acquired XXX companies to date.
Last acquisition by Chemed was XXXXXXXX, XXXXX XXXXX XXXXXX . Chemed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Chemed founded? | Chemed was founded in 1970. |
| Where is Chemed headquartered? | Chemed is headquartered in United States of America. |
| How many employees does Chemed have? | As of today, Chemed has 15.7K+ employees. |
| Who is the CEO of Chemed? | Chemed's CEO is Mr. Kevin J. Mcnamara. |
| Is Chemed publicy listed? | Yes, Chemed is a public company listed on NYS. |
| What is the stock symbol of Chemed? | Chemed trades under CHE ticker. |
| When did Chemed go public? | Chemed went public in 1982. |
| Who are competitors of Chemed? | Similar companies to Chemed include e.g. National Healthcare Corp, Regis Healthcare, Maternus-Kliniken, Addus HomeCare. |
| What is the current market cap of Chemed? | Chemed's current market cap is $8.4B |
| What is the current revenue of Chemed? | Chemed's last 12 months revenue is $2.5B. |
| What is the current revenue growth of Chemed? | Chemed revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Chemed? | Current revenue multiple of Chemed is 3.3x. |
| Is Chemed profitable? | Yes, Chemed is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Chemed? | Chemed's last 12 months EBITDA is $516M. |
| What is Chemed's EBITDA margin? | Chemed's last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of Chemed? | Current EBITDA multiple of Chemed is 16.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
